Noxopharm Ltd V.NOX

Primary Symbol: NOXOF

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

OTCPK:NOXOF - Post by User

Noxopharm Ltd > Final results for Marban are out

<< Previous

Bullboard Posts

Next >>

Comment by loonietuneson Dec 08, 2015 12:19pm

131 Views

Post# 24365332

RE:RE:Final results for Marban are out

This is the part of the NR that should comfort some of the nellies! Robert Wares, Niogold's president and chief executive officer, stated: "This final set of excellent results concludes our definition drilling campaign on Marban. The program included more than 72,000 metres of drilling and the Marban deposit delivered many new intersections in previously modelled barren rock. The drill program hence significantly improved the open pit potential of the deposit."

<< Previous

Bullboard Posts

Next >>

This junior mining stock offers billions in market exposure